Entropy-driven binding of gut bacterial β-glucuronidase inhibitors ameliorates irinotecan-induced toxicity

Hsien Ya Lin, Chia Yu Chen, Ting Chien Lin, Lun Fu Yeh, Wei Che Hsieh, Shijay Gao, Pierre Alain Burnouf, Bing Mae Chen, Tung Ju Hsieh, Punsaldulam Dashnyam, Yen Hsi Kuo, Zhijay Tu, Steve R. Roffler, Chun Hung Lin

研究成果: Article同行評審

15 引文 斯高帕斯(Scopus)


Irinotecan inhibits cell proliferation and thus is used for the primary treatment of colorectal cancer. Metabolism of irinotecan involves incorporation of β-glucuronic acid to facilitate excretion. During transit of the glucuronidated product through the gastrointestinal tract, an induced upregulation of gut microbial β-glucuronidase (GUS) activity may cause severe diarrhea and thus force many patients to stop treatment. We herein report the development of uronic isofagomine (UIFG) derivatives that act as general, potent inhibitors of bacterial GUSs, especially those of Escherichia coli and Clostridium perfringens. The best inhibitor, C6-nonyl UIFG, is 23,300-fold more selective for E. coli GUS than for human GUS (Ki = 0.0045 and 105 μM, respectively). Structural evidence indicated that the loss of coordinated water molecules, with the consequent increase in entropy, contributes to the high affinity and selectivity for bacterial GUSs. The inhibitors also effectively reduced irinotecan-induced diarrhea in mice without damaging intestinal epithelial cells.

期刊Communications Biology
出版狀態Published - 2021 12月

All Science Journal Classification (ASJC) codes

  • 醫藥(雜項)
  • 一般生物化學,遺傳學和分子生物學
  • 一般農業與生物科學


深入研究「Entropy-driven binding of gut bacterial β-glucuronidase inhibitors ameliorates irinotecan-induced toxicity」主題。共同形成了獨特的指紋。